Loading…
Employees: 1,133
Size Hvsen Biotechnology (300871.SZ) is a China Health Care company (Biotechnology) with a market value of $531M, the 3721st largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥17.61 on 6 Nov 2026.
Performance Over six months the shares fell 33.0%, against -9.5% for the median peer and -16.4% for the China market (cap-weighted) — 2nd lowest of 18 in its peer set.
Growth Revenue grew 2.4% over the last twelve months (peer median -2.2%); the operating margin is 16.9% (peer median -55.5%).
Valuation It trades at 11.2× forward earnings against a peer median of 22.6× (2nd cheapest of 6).
Capital Return on invested capital runs 1.8 points above its cost of capital (9.5% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.71B | CN¥1.68B | CN¥1.20B | CN¥1.02B | CN¥1.02B |
| Revenue growth | — | +40% | +18% | 0% | — |
| Gross profit | CN¥650M | CN¥484M | CN¥159M | CN¥164M | CN¥196M |
| EBITDA | n/a | CN¥398M | CN¥131M | CN¥127M | CN¥124M |
| Net income | CN¥324M | CN¥253M | -CN¥20.2M | CN¥16.8M | CN¥52.7M |
| Free cash flow | -CN¥159M | CN¥149M | -CN¥143M | -CN¥77.2M | -CN¥323M |
| Capital expenditure | CN¥420M | CN¥96.9M | CN¥194M | CN¥184M | CN¥429M |
| Total debt | CN¥678M | CN¥468M | CN¥1.20B | CN¥1.00B | CN¥984M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300871.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -17.1% | -12.2% | 6th lowest of 21 |
| 6-month return | -33.0% | -9.5% | 2nd lowest of 18 |
| Distance from 52-week high | -46.0% | -43.3% | 10th lowest of 21 |
| Revenue growth (TTM) | +2.4% | -2.2% | 6th highest of 14 |
| Operating margin | 16.9% | -55.5% | 2nd highest of 15 |
| Forward P/E | 11.2× | 22.6× | 2nd cheapest of 6 |
| ROIC minus cost of capital | +1.8 pp | -11.3 pp | 2nd highest of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hvsen Biotechnology 300871.SZ | China | $531M | -33% | +2% | 17% | 11.2× | n/a | n/a |
| Liaoning Dingjide Petrochemical 603255.SS | China | $530M | -15% | +70% | 5% | 19.2× | n/a | n/a |
| Valneva VLA.PA | France | $534M | -2% | -27% | -87% | n/a | n/a | n/a |
| Beijing Scitop Bio-Tech 300858.SZ | China | $526M | -25% | +4% | 8% | 22.6× | n/a | n/a |
| Sinotherapeutics 688247.SS | China | $537M | -14% | -17% | 0% | n/a | 31.6% | +7.0% |
| HanchorBio 7827.TW | Taiwan | $511M | n/a | n/a | -225% | 2.5× | n/a | n/a |
| Beijing Bohui Innovation Biotechnology 300318.SZ | China | $553M | -19% | +6% | -11% | n/a | n/a | n/a |
| LongBio Pharma (Suzhou) 1779.HK | Hong Kong | $554M | n/a | n/a | n/a | n/a | n/a | n/a |
| Shanghai Serum Bio-Technology 688163.SS | China | $507M | -11% | -1% | 26% | n/a | n/a | n/a |
| Neurogene NGNE | United States | $506M | -18% | -100% | n/a | n/a | n/a | n/a |
| DiaMedica Therapeutics DMAC | United States | $505M | +48% | n/a | n/a | n/a | n/a | n/a |
| Berry Genomics 000710.SZ | China | $504M | -5% | -2% | -24% | n/a | n/a | n/a |
| Qurient 115180.KS | South Korea | $503M | -59% | -20% | -517% | n/a | n/a | n/a |
| Crescent Biopharma CBIO | United States | $503M | -28% | n/a | -1,418% | n/a | n/a | n/a |
| Faeth Therapeutics FTH | United States | $570M | -6% | n/a | n/a | n/a | n/a | n/a |
| Alebund Pharmaceuticals (Jiangsu) 9637.HK | Hong Kong | $576M | n/a | +674% | -495% | n/a | n/a | n/a |
| Scinopharm Taiwan 1789.TW | Taiwan | $482M | -1% | -5% | -4% | 43.8× | 15.2% | +0.5% |
| CHO Pharma 6586.TWO | Taiwan | $480M | +57% | -47% | -17,694% | n/a | n/a | n/a |
| Monopar Therapeutics MNPR | United States | $479M | +12% | n/a | n/a | n/a | n/a | n/a |
| Climb Bio CLYM | United States | $591M | -10% | n/a | n/a | n/a | n/a | n/a |
| Genfit GNFT.PA | France | $593M | +19% | +28% | -130% | 79.3× | 40.0% | +143.5% |